Safety and Efficacy of Mobic® Ampoules in the Initiation of Treatment of Painful Exacerbations of Osteoarthritis, Rheumatoid Arthritis and Other Similar Painful Inflammatory Conditions

Overview

Study to determine the safety and efficacy of Mobic® ampoules in the initiation of treatment of painful exacerbations of osteoarthritis, rheumatoid arthritis and other similar painful inflammatory conditions.

Full Title of Study: “Meloxicam (MOBIC®) Ampoule Post Marketing Surveillance Study”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: March 2005

Interventions

  • Drug: Meloxicam
    • 7.5 mg or 15 mg

Arms, Groups and Cohorts

  • Meloxicam

Clinical Trial Outcome Measures

Primary Measures

  • Overall assessment of degree of pain on a 3-point scale
    • Time Frame: up to 3 days

Secondary Measures

  • Number of patients with adverse events
    • Time Frame: up to 3 days

Participating in This Clinical Trial

Inclusion Criteria

  • Painful acute exacerbations of inflammatory rheumatism (rheumatoid arthritis and ankylosing spondylitis), painful acute exacerbations of osteoarthritis and other similar conditions requiring acute treatment with an anti-inflammatory drug Exclusion Criteria:

  • none

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Boehringer Ingelheim
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.